文献速递儿科与产科急症

低剂量阿司匹林用于预防单胎初产妇早产(ASPIRIN):一项随机、双盲、安慰剂对照试验

Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet · 2020-01-01
一句话结论在低收入和中等收入国家,单胎初产妇于妊娠6周0天至13周6天开始每日服用阿司匹林81 mg,可降低37周前早产发生率(RR 0.89)和围产期死亡率。

ASPIRIN是一项在6个国家7个社区点开展的随机、双盲、安慰剂对照试验,纳入11 976名年龄14–40岁、超声确认孕周且为单胎活产妊娠的初产妇,于妊娠6周0天至13周6天随机分组,每日服用阿司匹林81 mg或安慰剂,直至妊娠36周7天或分娩。主要终点分析纳入有20周及以后妊娠结局者(改良意向性治疗),阿司匹林组5780例、安慰剂组5764例可评估。37周前早产在阿司匹林组668例(11.6%)、安慰剂组754例(13.1%),RR 0.89(95% CI 0.81–0.98),p=0.012。阿司匹林组围产期死亡率、胎儿丢失、34周前早产及34周前分娩合并妊娠期高血压疾病的发生率均降低,其他母儿不良事件两组相似。

要点

  • 单胎初产妇在妊娠6周0天至13周6天开始每日阿司匹林81 mg,37周前早产668/5780(11.6%)vs 安慰剂754/5764(13.1%),RR 0.89(95% CI 0.81–0.98),p=0.012
  • 围产期死亡率RR 0.86(95% CI 0.73–1.00),p=0.048;胎儿丢失(妊娠16周后至产后7天内婴儿死亡)RR 0.86(95% CI 0.74–1.00),p=0.039
  • 34周前早产RR 0.75(95% CI 0.61–0.93),p=0.039;34周前分娩合并妊娠期高血压疾病RR 0.38(95% CI 0.17–0.85),p=0.015
  • 其他母体及新生儿不良事件两组相似;严重不良事件在至少接受一剂药物或安慰剂的所有女性中评估
  • 研究人群为低收入和中等收入国家(印度2个点,刚果民主共和国、危地马拉、肯尼亚、巴基斯坦、赞比亚各1个点)的初产妇,不能直接外推至其他人群

适用人群与场景

  • 纳入:年龄14–40岁、超声确认孕周、单胎活产妊娠的初产妇,来自6个国家7个社区点(印度2个点,刚果民主共和国、危地马拉、肯尼亚、巴基斯坦、赞比亚各1个点)
  • 纳入孕周:妊娠6周0天至13周6天之间启动试验用药
  • 主要终点分析人群:随机分组且有20周及以后妊娠结局者(改良意向性治疗),阿司匹林组5780例、安慰剂组5764例
  • 严重不良事件分析人群:至少接受一剂药物或安慰剂的所有女性

诊断标准与关键阈值

  • 早产主要终点定义:妊娠37周前分娩的数量
  • 早期早产:妊娠34周前分娩
  • 胎儿丢失定义:妊娠16周后婴儿死亡及产后7天内死亡

处置流程与药物剂量

  • 阿司匹林组:阿司匹林81 mg每日口服,于妊娠6周0天至13周6天之间启动,持续至妊娠36周7天或分娩
  • 对照组:外观相同的安慰剂片,给药方式与疗程相同
  • 随机分组:1:1,按中心分层,由数据协调中心(美国北卡罗来纳州研究三角园区国际研究院)集中生成序列
  • 盲法:研究 staff、医疗提供者和患者均对治疗分配设盲

研究设计与关键结果

  • 研究类型:随机、多国、双盲、安慰剂对照试验(ASPIRIN),注册号ClinicalTrials.gov NCT02409680、印度临床试验注册CTRI/2016/05/006970
  • 筛选与随机:2016年3月23日至2018年6月30日筛选14 361名女性,随机11 976名(阿司匹林组5990例、安慰剂组5986例)
  • 主要终点:37周前早产阿司匹林组668/5780(11.6%) vs 安慰剂组754/5764(13.1%),RR 0.89(95% CI 0.81–0.98),p=0.012
  • 围产期死亡率:RR 0.86(95% CI 0.73–1.00),p=0.048
  • 胎儿丢失(妊娠16周后至产后7天内婴儿死亡):RR 0.86(95% CI 0.74–1.00),p=0.039
  • 34周前早产:RR 0.75(95% CI 0.61–0.93),p=0.039
  • 34周前分娩合并妊娠期高血压疾病:RR 0.38(95% CI 0.17–0.85),p=0.015
  • 其他母体及新生儿不良事件两组相似

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验(RCT)
  • 资助:Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对低收入和中等收入国家的单胎初产妇,于妊娠6周0天至13周6天启动每日阿司匹林81 mg可降低37周前早产发生率及围产期死亡率(作者结论)
  • 其他母体及新生儿不良事件两组相似,未观察到新的安全性信号
  • 该结果来自低收入和中等收入国家人群,原文未报告其他人群的适用性

指南或共识出处

  • ASPIRIN试验,ClinicalTrials.gov NCT02409680;Clinical Trial Registry-India CTRI/2016/05/006970

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Preterm birth remains a common cause of neonatal mortality, with a disproportionately high burden in low-income and middle-income countries. Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation.

METHODS: ASPIRIN was a randomised, multicountry, double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of pregnancy, in nulliparous women with an ultrasound confirming gestational age and a singleton viable pregnancy. Participants were enrolled at seven community sites in six countries (two sites in India and one site each in the Democratic Republic of the Congo, Guatemala, Kenya, Pakistan, and Zambia). Participants were randomly assigned (1:1, stratified by site) to receive aspirin or placebo tablets of identical appearance, via a sequence generated centrally by the data coordinating centre at Research Triangle Institute International (Research Triangle Park, NC, USA). Treatment was masked to research staff, health providers, and patients, and continued until 36 weeks and 7 days of gestation or delivery. The primary outcome of incidence of preterm birth, defined as the number of deliveries before 37 weeks' gestational age, was analysed in randomly assigned women with pregnancy outcomes at or after 20 weeks, according to a modified intention-to-treat (mITT) protocol. Analyses of our binary primary outcome involved a Cochran-Mantel-Haenszel test stratified by site, and generalised linear models to obtain relative risk (RR) estimates and associated confidence intervals. Serious adverse events were assessed in all women who received at least one dose of drug or placebo. This study is registered with ClinicalTrials.gov, NCT02409680, and the Clinical Trial Registry-India, CTRI/2016/05/006970.

FINDINGS: From March 23, 2016 to June 30, 2018, 14 361 women were screened for inclusion and 11 976 women aged 14-40 years were randomly assigned to receive low-dose aspirin (5990 women) or placebo (5986 women). 5780 women in the aspirin group and 5764 in the placebo group were evaluable for the primary outcome. Preterm birth before 37 weeks occurred in 668 (11·6%) of the women who took aspirin and 754 (13·1%) of those who took placebo (RR 0·89 [95% CI 0·81 to 0·98], p=0·012). In women taking aspirin, we also observed significant reductions in perinatal mortality (0·86 [0·73-1·00], p=0·048), fetal loss (infant death after 16 weeks' gestation and before 7 days post partum; 0·86 [0·74-1·00], p=0·039), early preterm delivery (<34 weeks; 0·75 [0·61-0·93], p=0·039), and the incidence of women who delivered before 34 weeks with hypertensive disorders of pregnancy (0·38 [0·17-0·85], p=0·015). Other adverse maternal and neonatal events were similar between the two groups.

INTERPRETATION: In populations of nulliparous women with singleton pregnancies from low-income and middle-income countries, low-dose aspirin initiated between 6 weeks and 0 days of gestation and 13 weeks and 6 days of gestation resulted in a reduced incidence of preterm delivery before 37 weeks, and reduced perinatal mortality.

FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Hoffman MK, Goudar SS, Kodkany BS, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020. PMID: 31982074. doi:10.1016/S0140-6736(19)32973-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。